Epimacular Brachytherapy for Neovascular AMD: The MERITAGE Study
Dr. David S. Boyer recently presented the 18 month clinical update from the on-going MERITAGE study, which is looking at the effect of adding Epimacular Brachytherapy (NeoVista, Inc - Newark, CA) to anti-VEGF injections for treating wet AMD. The objective of MERITAGE is two-fold: reduce the number of injections while maintaining vision. Data at 18 months, suggests that both objectives are being achieved.
2 comments for “Epimacular Brachytherapy for Neovascular AMD: The MERITAGE Study”